Status: Not yet recruiting
Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study
This is a single-center, retrospective, observational, real-world study. We collected general and clinical data of patients with advanced gastric cancer who were admitted to the First Affiliated Hospital of Zhengzhou University from January 2018 to July 2024.
Participants needed: 200
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Yongxu JiaUpdated: Feb 7, 2025
Eligibility criteria
Histologically confirmed metastatic or advanced GC/GEJC; [+4]
patients had other malignancies within the past 5 years; [+2]